PERSPECTA

News from every angle

← Back to headlines

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial

Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.

23 Feb, 09:53 — 23 Feb, 09:53
PostShare

Sources

Showing 1 of 3 sources
cnbcMostly Factual48d ago

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial

Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Read full article →

Coverage Timeline

First report: cnbc · 23 Feb, 09:53Full coverage: 3 · 2hWindow: 2h
Left-leaningCenterRight-leaning
cnbc23 Feb, 09:53First to report

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial

seeking-alpha23 Feb, 10:14

Biggest stock movers Monday: NVO, VNDA, and more

2h later
die-presse23 Feb, 12:07Latest update

Aktie bricht ein: Novo-Nordisks Abnehmspritze CagriSema enttäuscht [premium]

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

Truck Carrying Undeclared Fuel Seized at Tabaco Port, Philippines

just now

Philippines Affirms Sovereign Rights in Oil Exploration Agreements

just now

Philippines Assures Adherence to Laws in Joint Oil Exploration Talks

just now